Protein Nanoparticles

Engineered protein-based nanoparticles for drug delivery

153 companies 20 countries
S

Selecta Biosciences

Watertown, United States

Selecta Biosciences, Inc., founded in 2007 and based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company developing its proprietary ImmTOR nanoparticle platform to address a critical challenge in biologics therapy—unwanted immune responses that reduce treatment efficacy. Publicly traded on NASDAQ (SELB) with over $300 million in funding and 100-200 employees, Selecta has pioneered synthetic vaccine particles (SVP) that can selectively modulate immune responses, potentially enabling repeat administration of therapeutic proteins and gene therapies. The company emerged from research on how nanoparticle properties influence immune system activation, discovering that specific nanoparticle designs could induce immune tolerance rather than immunogenicity. Selecta's ImmTOR platform consists of biodegradable polymer nanoparticles incorporating immunomodulatory small molecules (typically rapamycin analogs) that are taken up by immune cells, inducing tolerance to co-administered therapeutic agents. This approach addresses a major limitation of protein therapeutics and gene therapies—the development of neutralizing antibodies that reduce or eliminate treatment efficacy with repeated dosing. For example, many patients with gout receiving enzyme replacement therapy develop anti-drug antibodies that neutralize the therapeutic enzyme, requiring treatment discontinuation. Selecta's lead program, SEL-212, combines ImmTOR nanoparticles with pegsiticase enzyme therapy for severe gout, with clinical trials demonstrating reduced immunogenicity and improved sustained therapeutic response. The company has expanded its platform to address immunogenicity challenges in gene therapy, where immune responses against viral vectors or therapeutic proteins can limit treatment durability. Selecta has established partnerships with major pharmaceutical companies including Sarepta Therapeutics and Asklepios BioPharmaceutical to apply ImmTOR technology to gene therapy programs for muscular dystrophies and other genetic diseases. The company's nanoparticles are engineered with precise sizes (typically 200-500 nanometers), controlled drug loading, and surface properties optimized for uptake by specific immune cell populations. Selecta has developed manufacturing processes producing clinical-grade ImmTOR nanoparticles at scales required for therapeutic applications, addressing a key challenge in nanomedicine translation. The company's approach represents sophisticated application of nanotechnology principles—using nanoparticle properties to program specific biological responses rather than simply delivering drugs. Selecta's clinical programs have generated important data on how synthetic nanoparticles can modulate human immune systems, contributing to fundamental understanding of nanoparticle immunology. As gene therapies and protein biologics become increasingly important in medicine, addressing immunogenicity challenges will be crucial for enabling repeat dosing and expanding patient populations. Selecta's ImmTOR platform offers a potentially broadly applicable solution to this critical problem, positioning the company at the intersection of nanomedicine and immunotherapy, two of the most promising areas in biopharmaceutical development.

NASDAQ: SELB
N

NanoViricides

Shelton, United States

Developer of nanoviricide drugs designed to attack and destroy viruses

NYSE: NNVC
N

Nanosphere Health Sciences

Vancouver, Canada

Developer of NanoSphere Delivery System for enhanced bioavailability of cannabinoids

T

Tarveda Therapeutics

Watertown, United States

Developer of miniature drug conjugates for targeted cancer therapy

N

NanoXact

San Diego, United States

Brand offering precisely manufactured nanoparticles for life science applications

N

NanoLight Technologies

Pinetop, United States

NanoLight Technologies, founded in 1995 in Pinetop, Arizona, is a specialized manufacturer of advanced bioluminescent and fluorescent nanoparticle probes for biological research and imaging applications. With nearly three decades of experience, the company has become a trusted supplier of high-quality molecular imaging reagents that enable researchers to visualize biological processes at the cellular and molecular levels. NanoLight's flagship NanoLuc technology represents a breakthrough in bioluminescent reporters, offering one of the smallest and brightest bioluminescent proteins available for research applications. This engineered luciferase enzyme, when combined with its substrate coelenterazine, produces intense luminescence that enables sensitive detection of cellular events, protein interactions, and gene expression with minimal background interference. The company's coelenterazine substrates, available in multiple variants optimized for different applications, serve as essential reagents for numerous bioluminescence-based assays. These small molecule substrates are chemically synthesized to high purity standards, ensuring reliable performance in demanding research applications. NanoLight also manufactures fluorescent nanoparticle probes that leverage quantum confinement effects and surface chemistry modifications to create bright, photostable markers for cellular imaging, flow cytometry, and immunoassays. These nanoparticles, typically ranging from 10-100 nanometers in diameter, offer advantages over conventional organic dyes including enhanced brightness, resistance to photobleaching, and tunable emission wavelengths. The company's products support diverse research areas including cancer biology, neuroscience, drug discovery, and infectious disease research. As a privately-held company with 10-50 employees, NanoLight maintains close relationships with the research community, providing technical support and custom synthesis services. The company's contribution to nanotechnology lies in developing and manufacturing nanoscale imaging tools that make invisible biological processes visible, accelerating scientific discovery across life sciences disciplines.

N

Nippon Kayaku

Tokyo, Japan

Pharmaceutical and chemical company with nanomedicine portfolio including micellar formulations

TSE: 4272
N

Nanovex Biotechnologies

Oviedo, Spain

Biotech company developing extracellular vesicle and exosome-based delivery systems

W

Wyatt Technology

Santa Barbara, United States

US manufacturer of light scattering instruments for nanoparticle characterization

S

SandboxAQ

Palo Alto, United States

Spun out of Alphabet, developing quantum and AI technologies

A

Aquaporin A/S

Kongens Lyngby, Denmark

Pioneer in biomimetic water filtration using aquaporin proteins

NASDAQ Copenhagen: AQP public
N

NanoMedica

San Diego, United States

Developer of nanoparticle-based cancer therapeutics

N

Nanoform Finland

Helsinki, Finland

Developer of controlled expansion of supercritical solutions for drug nanoforming

NASDAQ Helsinki: NANOFH public
N

NanoMedTrix

Berlin, Germany

Nanoparticle-based immunotherapy platform

E

Exicure

Chicago, United States

Spherical nucleic acid therapeutics platform

N

Nano Therapeutics

Mumbai, India

Nano-based drug delivery systems for cancer therapy

L

L'Oréal Nano

Paris, France

Pioneering nanotechnology in cosmetics and skincare

EURONEXT: OR public
N

Nanovetores

Florianópolis, Brazil

Nanoencapsulation technology for cosmetics

N

Nanoimmunotech

A Coruña, Spain

Immunomagnetic nanoparticles for diagnostics

Q

Quantum-Si

Branford, United States

Single-molecule protein sequencing

NASDAQ: QSI public
N

NanoBio (BlueWillow Biologics)

Ann Arbor, United States

Nanoemulsion-based vaccines and therapeutics

N

NanoImaging Services

San Diego, United States

Cryo-EM and negative stain imaging

N

Nanoform

Helsinki, Finland

Controlled expansion of supercritical solutions for drug nanoparticle engineering

Nasdaq Nordic: NANOFH public
C

Celgene (Bristol-Myers Squibb)

Summit, United States

Oncology and immunology therapeutics using nanoparticle formulations

NYSE: BMY public
A

Abraxis BioScience

Los Angeles, United States

Pioneer of nanoparticle albumin-bound (nab) technology for cancer drugs

B

BioDynamics Laboratory

Tokyo, Japan

Nanogel and polymer technology for drug delivery applications

N

Nanomerics

London, United Kingdom

Molecular envelope technology for enhanced drug delivery

M

Midatech Pharma

Abingdon, United Kingdom

Gold nanoparticle drug conjugates for oncology therapeutics

AIM: MTPH public
C

Ceramisphere

Sydney, Australia

Ceramic nanoparticle drug delivery systems

A

Ajinomoto Bio-Pharma Services

San Diego, United States

CDMO for oligonucleotides and ADCs

D

Daiichi Sankyo

Tokyo, Japan

Antibody-drug conjugates and nanomedicine oncology

TSE: 4568 public
E

Eisai Co.

Tokyo, Japan

Neurology and oncology with nanoformulation research

TSE: 4523 public
L

LG Chem Life Sciences

Seoul, South Korea

Life sciences division with nanoparticle drug delivery

KRX: 051910 public
S

Samyang Biopharmaceuticals

Seoul, South Korea

Genexol-PM polymeric micelle nanoparticle drugs

KRX: 000070 public
C

Celltrion

Incheon, South Korea

Biosimilars and antibody drug conjugates

KRX: 068270 public
D

Daewoong Pharmaceutical

Seoul, South Korea

Innovative drug delivery and biologics

KRX: 069620 public
W

WuXi AppTec

Shanghai, China

Global CRO/CDMO with nanomedicine manufacturing capabilities

HKEX: 2359 public
A

Asymchem Laboratories

Tianjin, China

CDMO services including nanoparticle formulations

HKEX: 6821 public
L

Livzon Pharmaceutical

Zhuhai, China

Chinese pharma with microsphere and nanoparticle delivery

SZSE: 000513 public
O

Oncobiologics

Cranbury, United States

Biosimilar development with advanced formulation technology

N

NanoSyrinx

Sheffield, United Kingdom

Bacterial contractile injection system for protein delivery

U

University of São Paulo Nanomedicine

São Paulo, Brazil

Nanomedicine research at South America's largest university

research
S

Symrise

Holzminden, Germany

Fragrances, flavors, and cosmetic ingredients

XETRA: SY1 public
S

Selecta Biosciences

Watertown, United States

ImmTOR biodegradable nanoparticles for immune tolerance induction

NASDAQ: SELB public
H

Halozyme Therapeutics

San Diego, United States

ENHANZE technology enabling subcutaneous delivery of biologics

NASDAQ: HALO public
L

Lipocine

Salt Lake City, United States

Lipid-based oral drug delivery platform for poorly bioavailable compounds

NASDAQ: LPCN public
N

Novavax

Gaithersburg, United States

Recombinant nanoparticle vaccine technology for infectious diseases

NASDAQ: NVAX public
V

Vaxart

South San Francisco, United States

Oral vaccine platform using recombinant vectors and nanoparticle technology

NASDAQ: VXRT public
S

Serum Institute of India

Pune, India

World's largest vaccine manufacturer exploring nanoparticle vaccine technology

B

Bharat Biotech

Hyderabad, India

Vaccine developer with nanoparticle-based vaccine platforms

S

SK Bioscience

Seongnam, South Korea

Vaccine and biopharmaceutical company with nanoparticle vaccine capabilities

KRX: 302440 public
P

Particle Sciences

Bethlehem, United States

Drug delivery and formulation development including nanoparticle systems

C

Curia Global

Albany, United States

Contract research and manufacturing with nanoparticle drug delivery expertise

P

Polymun Scientific

Klosterneuburg, Austria

CDMO specializing in liposomal and lipid nanoparticle formulations

L

Lipoid GmbH

Ludwigshafen, Germany

Manufacturer of high-purity phospholipids for drug delivery and diagnostics

B

BioVision

Milpitas, United States

Life science reagents including nanoparticle-based assays and detection kits

C

Creative Diagnostics

Shirley, United States

Diagnostic reagents including gold and magnetic nanoparticles for lateral flow assays

N

Nanocs

New York, United States

PEGylation reagents and functionalized nanoparticles for biomedical applications

S

Spherotech

Lake Forest, United States

Microspheres and nanoparticles for flow cytometry, diagnostics, and research

B

Bangs Laboratories

Fishers, United States

Microspheres and polymer beads for diagnostics and flow cytometry

B

Beckman Coulter Diagnostics

Brea, United States

Clinical diagnostics with nanoparticle-based immunoassays and flow cytometry

NYSE: DHR public
B

Bio-Techne

Minneapolis, United States

Life science tools including nanoparticle-based reagents and spatial biology

NASDAQ: TECH public
P

PerkinElmer

Waltham, United States

Analytical instruments and diagnostics with nanoparticle-based assay technologies

NYSE: PKI public
S

Sartorius

Göttingen, Germany

Bioprocess and lab equipment with nanofiltration and membrane technology

XETRA: SRT public
B

BBI Solutions

Cardiff, United Kingdom

Gold nanoparticles and reagents for in-vitro diagnostics

R

Refeyn

Oxford, United Kingdom

Mass photometry for label-free protein characterization

D

Denali Therapeutics

South San Francisco, United States

Neurodegeneration drugs using Transport Vehicle BBB-crossing technology

NASDAQ: DNLI public
V

Voyager Therapeutics

Cambridge, United States

AAV capsid engineering for CNS gene therapy delivery

NASDAQ: VYGR public
4

4D Molecular Therapeutics

Emeryville, United States

Therapeutic vectors using Directed Evolution AAV capsid discovery

NASDAQ: FDMT public
B

Bluebird Bio

Somerville, United States

Gene therapy using lentiviral vectors for genetic diseases

NASDAQ: BLUE public
C

Curia Global

Albany, United States

CDMO with nanoparticle and complex formulation capabilities

C

Chimeron Bio

Philadelphia, United States

Chimeric viral vectors for improved gene therapy delivery

B

Bicycle Therapeutics

Cambridge, United Kingdom

Bicyclic peptide platform for targeted drug delivery

NASDAQ: BCYC public
P

PeptiDream

Kawasaki, Japan

Peptide Drug Discovery Platform System for macrocyclic therapeutics

TSE: 4587 public
S

Sorrento Therapeutics

San Diego, United States

Biopharmaceutical with ADC and nanoparticle delivery platforms

M

Mersana Therapeutics

Cambridge, United States

Antibody drug conjugates using Dolasynthen platform

NASDAQ: MRSN public
A

ADC Therapeutics

Lausanne, Switzerland

Antibody drug conjugates for hematological malignancies

NYSE: ADCT public
S

Seagen

Bothell, United States

ADC pioneer (Adcetris, Padcev) acquired by Pfizer

I

ImmunoGen

Waltham, United States

ADC technology company acquired by AbbVie

S

Synaffix

Amsterdam, Netherlands

ADC technology platform using GlycoConnect and toxSYN

S

Sutro Biopharma

South San Francisco, United States

Cell-free protein synthesis for site-specific ADC conjugation

NASDAQ: STRO public
B

Bioasis Technologies

Guilford, Canada

xB3 platform for blood-brain barrier crossing drug delivery

A

AngioChem

Montreal, Canada

Peptide-drug conjugates for CNS delivery across BBB

A

Annexon Biosciences

Brisbane, United States

Complement cascade inhibitors for neurological diseases

NASDAQ: ANNX public
R

Regenxbio

Rockville, United States

AAV gene therapy using NAV Technology Platform

NASDAQ: RGNX public
M

MeiraGTx

New York, United States

Gene therapy for inherited retinal diseases and beyond

NASDAQ: MGTX public
K

Krystal Biotech

Pittsburgh, United States

Gene therapies using HSV-1 vectors for skin diseases

NASDAQ: KRYS public
S

Sarepta Therapeutics

Cambridge, United States

Gene therapy and RNA therapeutics for muscular dystrophies

NASDAQ: SRPT public
S

Solid Biosciences

Charlestown, United States

Gene therapy for Duchenne muscular dystrophy

NASDAQ: SLDB public
U

Ultragenyx Pharmaceutical

Novato, United States

Gene therapy and biologics for rare genetic diseases

NASDAQ: RARE public
R

Rocket Pharmaceuticals

Cranbury, United States

Lentiviral and AAV gene therapies for rare diseases

NASDAQ: RCKT public
G

Genethon

Evry, France

Non-profit gene therapy research laboratory

research
F

Freeline Therapeutics

Stevenage, United Kingdom

AAV gene therapy for liver-targeted diseases

NASDAQ: FRLN public
O

Orchard Therapeutics

London, United Kingdom

Hematopoietic stem cell gene therapy for rare diseases

NASDAQ: ORTX public
B

BICO Group (Cellink)

Gothenburg, Sweden

Life science technology with bioprinting and bioinks for tissue engineering and drug discovery

OMX: BICO public
U

Ultragenyx Pharmaceutical

Novato, United States

Biopharmaceutical company developing novel products for rare and ultra-rare diseases

NASDAQ: RARE public
B

Biomarin Pharmaceutical

San Rafael, United States

Global biotechnology company developing therapies for rare genetic diseases

NASDAQ: BMRN public
V

Vertex Pharmaceuticals

Boston, United States

Global biotechnology company focused on cystic fibrosis and gene editing therapies

NASDAQ: VRTX public
B

Bristol Myers Squibb Cell Therapy

Summit, United States

Global biopharmaceutical company with leading CAR T cell therapy franchise

NYSE: BMY public
L

Legend Biotech

Somerset, United States

Global biotechnology company developing novel cell therapies for oncology

NASDAQ: LEGN public
A

Allogene Therapeutics

South San Francisco, United States

Clinical-stage biotechnology company pioneering allogeneic CAR T cell therapies

NASDAQ: ALLO public
L

Lyell Immunopharma

South San Francisco, United States

T cell reprogramming company developing next-generation cell therapies for solid tumors

NASDAQ: LYEL public
A

Adicet Bio

Menlo Park, United States

Clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies

NASDAQ: ACET public
D

Daiichi Sankyo ADC

Tokyo, Japan

Global pharmaceutical company with leading ADC technology platform

TSE: 4568 public
E

Exelixis

Alameda, United States

Oncology company developing transformative cancer treatments

NASDAQ: EXEL public
R

Resilience

San Diego, United States

Biomanufacturing company building sustainable network for complex medicine production

C

Catalent Cell and Gene

Somerset, United States

Global CDMO offering cell therapy, gene therapy, and viral vector manufacturing

W

WuXi Advanced Therapies

Shanghai, China

Global contract development and manufacturing organization for advanced therapies

HKEX: 2359 public
u

uniQure

Amsterdam, Netherlands

Gene therapy company developing AAV-based treatments for severe genetic diseases

NASDAQ: QURE public
R

Rocket Pharmaceuticals

Cranbury, United States

Gene therapy company developing treatments for rare childhood diseases

NASDAQ: RCKT public
A

Asklepios BioPharmaceutical

Research Triangle Park, United States

Gene therapy company developing AAV-based treatments for genetic diseases

A

Abeona Therapeutics

New York, United States

Clinical-stage biopharmaceutical company developing gene therapies for rare diseases

NASDAQ: ABEO public
L

Lexeo Therapeutics

New York, United States

Gene therapy company developing treatments for cardiac and neurological diseases

NASDAQ: LXEO public
N

Neurogene

New York, United States

Gene therapy company developing treatments for rare neurological diseases in children

NASDAQ: NGNE public
S

Sana Biotechnology

Seattle, United States

Biotechnology company engineering cells to treat disease using in vivo and ex vivo approaches

NASDAQ: SANA public
T

Taysha Gene Therapies

Dallas, United States

Gene therapy company developing treatments for monogenic CNS diseases

NASDAQ: TSHA public
B

Beyond Meat

El Segundo, United States

Plant-based meat company with products designed to replicate animal protein

NASDAQ: BYND public
P

Perfect Day

Berkeley, United States

Precision fermentation company producing animal-free dairy proteins

C

Clara Foods

San Francisco, United States

Precision fermentation company producing animal-free egg proteins

M

Motif FoodWorks

Boston, United States

Food ingredient company using biotech to create meat and dairy alternatives

N

Nature's Fynd

Chicago, United States

Fermentation company producing Fy protein from fungi discovered in Yellowstone

A

Air Protein

San Mateo, United States

Company making protein from air using NASA-inspired technology

S

Solar Foods

Helsinki, Finland

Finnish company producing Solein protein from CO2 and electricity

R

Ripple Foods

Emeryville, United States

Pea protein milk company providing sustainable dairy alternatives

M

Mori

Boston, United States

Food preservation company using silk protein coating technology

T

Tyson Ventures

Springdale, United States

Tyson Foods venture capital arm investing in food technology innovation

NYSE: TSN public
A

ADM

Chicago, United States

Global food processing and ingredients company with alternative protein investments

NYSE: ADM public
C

Cargill

Wayzata, United States

Global food corporation with significant investments in food technology and alternatives

I

Ingredion

Westchester, United States

Ingredients company providing starches, sweeteners, and plant-based solutions

NYSE: INGR public
K

Kerry Group

Tralee, Ireland

Irish food ingredients company providing taste and nutrition solutions

ISE: KYGA public
B

Bolt Threads

Emeryville, United States

Biotechnology company creating sustainable materials inspired by nature

M

Modern Meadow

Nutley, United States

Biofabrication company creating sustainable leather alternatives

E

Eat Just

San Francisco, United States

Plant-based egg and cultivated meat company

I

Indigo Agriculture

Boston, United States

Agricultural technology company using microbiology and carbon credits

Y

Ynsect

Evry, France

Insect farming company producing protein from mealworms

I

InnovaFeed

Paris, France

Insect protein producer for aquaculture and pet food

C

Califia Farms

Los Angeles, United States

Plant-based beverage company specializing in oat and almond milk products

G

Good Catch

New York, United States

Plant-based seafood company making fish alternatives from legumes

A

Agrinos

Davis, United States

Biological crop inputs

N

Nanotope

Evanston, United States

Self-assembling peptide nanomaterials

N

Nanoligent

Leuven, Belgium

Oncology nanodrug development

E

Exsilio Therapeutics

Boston, United States

mRNA platform for revocable genetic medicines

C

Cour Pharmaceutical

Chicago, United States

Particle platforms enabling immune targeting for inflammatory and immune applications

R

Revalesio Corporation

Tacoma, United States

Oxygen delivery technology at nano-scale for therapeutic applications

B

BioPact

Delft, Netherlands

Nanoformulation technology for drug delivery applications

M

Mulder Lab

Eindhoven, Netherlands

Nanomedicine research and development services

P

Poly-Dtech

Strasbourg, France

Fluorescent nanoparticle-based immunoassays and lateral flow tests for biomarker detection

A

Adocia

Lyon, France

BioChaperone nanoformulation technology for improved insulin delivery

T

Tandem Nano

Boston, United States

Nanoformulation delivery solutions for agriculture and pharmaceuticals

E

Evox Therapeutics

Oxford, United Kingdom

DeliverEX platform for engineered exosome therapeutics

A

Aruna Bio

Athens, United States

Neural-derived exosomes for CNS drug delivery crossing BBB

B

BioMagnetic Solutions

State College, United States

Magnetic nanoparticle solutions for bioseparation and diagnostics

M

Micromod Partikeltechnologie

Rostock, Germany

Magnetic micro and nanoparticles for life science applications